PD173074

For research use only.

Licensed by Pfizer Catalog No.S1264

83 publications

PD173074 Chemical Structure

CAS No. 219580-11-7

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src. PD173074 reduces proliferation and promotes apoptosis in gastric cancer cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 98 In stock
USD 70 In stock
USD 120 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's PD173074 has been cited by 83 publications

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src. PD173074 reduces proliferation and promotes apoptosis in gastric cancer cells.
Targets
FGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
~25 nM 100 nM-200 nM
In vitro

PD173074 is an ATP-competitive inhibitor of FGFR1 with Ki of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. [1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. [2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. [3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1581 NEfvTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMEGyNlUh|ryP Ml7LV2FPT0WU
KG-1 NYjPXpI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37R[WlEPTB;MD6wOVEzQSEQvF2= NGPSblVUSU6JRWK=
MFM-223 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP1TWM2OD1yLkKxOVc3KM7:TR?= NH3BPJFUSU6JRWK=
EoL-1-cell NV\VbFBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwM{K5PFQh|ryP NUXx[nJ4W0GQR1XS
ECC10 M{\4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILsUFVKSzVyPUCuN|M5QThizszN NVGySo12W0GQR1XS
H-EMC-SS NH3vS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO0SG9UUUN3ME2wMlM1PzF3IN88US=> NH;0WW9USU6JRWK=
AN3-CA M3vIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwNECxN|Mh|ryP MWPTRW5ITVJ?
HuO-3N1 NYD3UlZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjEZ5B1UUN3ME2wMlU1PjV|IN88US=> MVvTRW5ITVJ?
RT-112 NF2wcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK1WploUUN3ME2wMlU1PzBzIN88US=> NIfhZ5RUSU6JRWK=
NEC8 Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDRTWM2OD1yLkW2Nlg6KM7:TR?= NFvlcVRUSU6JRWK=
D-263MG NWrQU3N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3WTWM2OD1yLkexNVU6KM7:TR?= MXLTRW5ITVJ?
SW962 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoC3TWM2OD1yLke4PVg5KM7:TR?= NHK3W3RUSU6JRWK=
BV-173 M{DSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nTVWlEPTB;MD64OFYzOyEQvF2= NFr6d29USU6JRWK=
MFE-280 NHWxUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[zdVB7UUN3ME2wMlg2QDd{IN88US=> MoK1V2FPT0WU
HuH-7 NF76ZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zQOGlEPTB;MT6yOFQ3PCEQvF2= MV3TRW5ITVJ?
RS4-11 NUP3XIhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwM{O4PFYh|ryP MmTVV2FPT0WU
DMS-114 M{LGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j0UmlEPTB;MT6zOlc{PyEQvF2= NFTLO25USU6JRWK=
MSTO-211H NULQfHpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPCTWM2OD1zLkS3N|c5KM7:TR?= NIfFTHJUSU6JRWK=
DU-145 NY[zWHVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLjTWM2OD1zLkW4NlE4KM7:TR?= NIjMenJUSU6JRWK=
A172 M2jtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn1TWM2OD1zLkewN|U2KM7:TR?= MVfTRW5ITVJ?
SBC-1 NGnJfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJwMEm0JO69VQ>? M2fyWHNCVkeHUh?=
H9 MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TMS2lEPTB;Mj6xOFMxPiEQvF2= NGfrWFdUSU6JRWK=
NCI-SNU-1 NV3iVHpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfvW5QxUUN3ME2yMlE5Ozl2IN88US=> M1nZXnNCVkeHUh?=
NCI-H720 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;ZfmlEPTB;Mj6yNVI5OyEQvF2= MoDXV2FPT0WU
HCC2218 MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\KTWM2OD1{LkO3PVM6KM7:TR?= M4n0OXNCVkeHUh?=
G-401 M2Xs[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\NRZRKSzVyPUKuOFcyQDlizszN MVXTRW5ITVJ?
MPP-89 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPZTZRKSzVyPUKuOFg{PjRizszN MoHlV2FPT0WU
697 M3PKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DsXWlEPTB;Mj62OVM{OSEQvF2= NYjBPYZpW0GQR1XS
KARPAS-45 NFfxS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3STWM2OD1{LkewO|Q4KM7:TR?= NEHtSoFUSU6JRWK=
MG-63 NHW5eI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJwOUSyOlIh|ryP NV71TlR2W0GQR1XS
NTERA-S-cl-D1 NFjtcYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TW[GlEPTB;Mz6wN|Q4OiEQvF2= M1PBO3NCVkeHUh?=
G-402 NXTEXIh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO4TWM2OD1|LkGyO|I4KM7:TR?= M3m1bnNCVkeHUh?=
NKM-1 M4D1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nHSGlEPTB;Mz6xN|U3PCEQvF2= MmnyV2FPT0WU
RH-18 NVzIS|M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e5RmlEPTB;Mz6xPVU6QCEQvF2= M3;Nd3NCVkeHUh?=
NCI-H1092 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTNwMUm2PUDPxE1? MlnVV2FPT0WU
RPMI-8226 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLYSYdDUUN3ME2zMlI{PDR5IN88US=> M1m0ZnNCVkeHUh?=
GAMG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTNwNE[1O|Yh|ryP NYrNVJZFW0GQR1XS
HH MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTNwNEe2O|Yh|ryP NUi1RY1DW0GQR1XS
RO82-W-1 NFHJfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTNwNEm4OVUh|ryP NECwe4JUSU6JRWK=
CCRF-CEM M1\hNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP1TWM2OD1|LkWwOFg5KM7:TR?= M1PDeHNCVkeHUh?=
NBsusSR MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PvemlEPTB;Mz62N|k3QSEQvF2= MV3TRW5ITVJ?
CHL-1 NX7QXGdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTNwNkW3PVkh|ryP M4POS3NCVkeHUh?=
LK-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLPTWM2OD1|Lk[3NVM{KM7:TR?= MkXrV2FPT0WU
Hs-578-T NI[zT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXyeI1TUUN3ME2zMlY4QDd|IN88US=> NEfQO3NUSU6JRWK=
CTB-1 NYrxZ3VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfyfWRQUUN3ME2zMlgxODVzIN88US=> MmHwV2FPT0WU
ES5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTNwOEO2N|ch|ryP NIXLTHBUSU6JRWK=
A204 NWXJRXBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTNwOUKwO|Uh|ryP NYnNU4NZW0GQR1XS
SW780 NH:2N4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW0RXlKSzVyPUOuPVIzPDVizszN M3fZbHNCVkeHUh?=
EW-3 NHHqepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTNwOUi5NlMh|ryP M1TNT3NCVkeHUh?=
A704 NHvtfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr3TWM2OD12LkK4O|I{KM7:TR?= NGTVblRUSU6JRWK=
LU-139 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXKZ29ZUUN3ME20MlMyPTN2IN88US=> NEjXeWdUSU6JRWK=
CAL-72 M{C3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;QXGlEPTB;ND60NVc1PiEQvF2= M1LjNXNCVkeHUh?=
D-336MG MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETWdoNKSzVyPUSuOFY5OTdizszN NIjoUmJUSU6JRWK=
LAMA-84 M3e1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlS3TWM2OD12LkWzN|Eh|ryP NWDwN|k3W0GQR1XS
GI-ME-N MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHEXnc5UUN3ME20MlU1QDFizszN M1;2dHNCVkeHUh?=
KM-H2 M3fHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjtb5hZUUN3ME20MlU2OjJ{IN88US=> MXXTRW5ITVJ?
NCI-H209 M2nac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL2SWhKSzVyPUSuOVgzQDNizszN M3GxenNCVkeHUh?=
IGROV-1 M2jQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfKe|JKSzVyPUSuPFcyPjhizszN Mke5V2FPT0WU
L-363 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\HU2lEPTB;ND65OlY3PSEQvF2= MV\TRW5ITVJ?
SK-MEL-3 NI[xNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\INGlEPTB;NT6yOFA3KM7:TR?= NH2wZ2pUSU6JRWK=
HuO9 NH\VeGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzuTWM2OD13LkO4PFQ{KM7:TR?= NV7ZNnhCW0GQR1XS
NOS-1 M2jOd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NESxUINKSzVyPUWuO|I6OjdizszN NIXxOIdUSU6JRWK=
NCI-H1770 NHrFZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXjTWM2OD13Lkm1NFMzKM7:TR?= NVXR[2J7W0GQR1XS
SF126 MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTZwMkG0NFYh|ryP MXzTRW5ITVJ?
ML-2 NXXuSVhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTZwMkS5O|ch|ryP Mn3SV2FPT0WU
CHP-134 NVrnd5BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[yTWM2OD14LkK1NVgzKM7:TR?= NYPqWIVUW0GQR1XS
NCI-H1355 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\rXlNUUUN3ME22MlQyPzN|IN88US=> MVvTRW5ITVJ?
TE-12 M1TGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIO1SVFKSzVyPU[uO|I3PzFizszN M17seHNCVkeHUh?=
A4-Fuk Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLTTWM2OD14LkezNVQzKM7:TR?= M1L4eHNCVkeHUh?=
MV-4-11 NVu3NFNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWno[|EyUUN3ME22Mlc3PjJ4IN88US=> NVnhW4hPW0GQR1XS
SK-UT-1 NUDVfZdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrkT2I3UUN3ME22MlkyPzh2IN88US=> NWmzU49KW0GQR1XS
J-RT3-T3-5 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fVdWlEPTB;Nz6wO|c3PCEQvF2= MnHPV2FPT0WU
ME-180 MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjwTWM2OD15LkGwOFA1KM7:TR?= Ml7oV2FPT0WU
SK-MEL-28 M1;SS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7TTWM2OD15LkO3PFE6KM7:TR?= M33hVHNCVkeHUh?=
HAL-01 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTdwNEizOFEh|ryP M4TPb3NCVkeHUh?=
ES8 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nQXGlEPTB;Nz62PVYzPiEQvF2= NFzKTYxUSU6JRWK=
DB NX;tZ2N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTnbY5uUUN3ME24MlEyPTB2IN88US=> MmOxV2FPT0WU
SK-NEP-1 M3vqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:3TJVKSzVyPUiuOFgyPDlizszN MmHGV2FPT0WU
COR-L88 NUHEdFRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37RdWlEPTB;OD61NFk5OSEQvF2= MXPTRW5ITVJ?
LB1047-RCC MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRThwNUKyNVIh|ryP MX;TRW5ITVJ?
NCI-H520 NHzDeINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrVWFBUUUN3ME24MlYzOTV5IN88US=> MX\TRW5ITVJ?
SW954 MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPmbXZIUUN3ME24MlY6Pzh4IN88US=> NWPVeFlLW0GQR1XS
TE-6 NHLLR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fPW2lEPTB;OD63OVE1OyEQvF2= M{LNUnNCVkeHUh?=
D-283MED MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\4[VVKSzVyPUmuNFY2OzRizszN MWTTRW5ITVJ?
DBTRG-05MG MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n0OmlEPTB;OT6wPVYxPyEQvF2= MYXTRW5ITVJ?
NCI-H446 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37HO2lEPTB;OT6yPVUzPiEQvF2= MYfTRW5ITVJ?
HOS NYKyXnlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXBcYRKSzVyPUmuN|UyOzRizszN M2X4dXNCVkeHUh?=
ES4 MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTlwNUC1PVUh|ryP MUPTRW5ITVJ?
EW-13 NFGze21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzYTWM2OD17Lki5NFU2KM7:TR?= NH\nZWhUSU6JRWK=
IST-MES1 NUnRNVdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLoOIxKSzVyPUmuPVQ2OzRizszN MoX5V2FPT0WU
CAS-1 M4jLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTlwOUe2OVkh|ryP M1jLOHNCVkeHUh?=
EM-2 M32zfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vNR2lEPTB;MUCuNVM6OyEQvF2= MlvvV2FPT0WU
SW948 M2TSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFyLkG4PFIh|ryP Mmm5V2FPT0WU
OAW-42 NIizVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jzd2lEPTB;MUCuOVI3PyEQvF2= M2XT[3NCVkeHUh?=
BE-13 M1TyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HjV2lEPTB;MUCuOlU4PiEQvF2= M2HwW3NCVkeHUh?=
KU812 Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LrNGlEPTB;MUCuO|M6OSEQvF2= NY\JRmQ1W0GQR1XS
SK-MEL-30 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXKUoRjUUN3ME2xNE45QTBzIN88US=> M33se3NCVkeHUh?=
A2780 M4HIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fKO2lEPTB;MUGuNFMxQCEQvF2= NVPYdXZEW0GQR1XS
TGBC24TKB MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLZNo1KSzVyPUGxMlA4OzdizszN MmH3V2FPT0WU
GOTO MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;MTWM2OD1zMT6yNFg1KM7:TR?= NXG5Z2hMW0GQR1XS
NCI-H526 NEfDOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\peWlEPTB;MUGuN|g{PyEQvF2= MmnJV2FPT0WU
BHT-101 MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjsTWM2OD1zMT60OFU3KM7:TR?= M2DsUXNCVkeHUh?=
NCI-H1155 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFzLkS5OFch|ryP Mni1V2FPT0WU
MCF7 NY\5UI9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFzLk[xOlch|ryP NVnIO4FKW0GQR1XS
MKN45 NUDiZ5U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnKT5hKSzVyPUGxMlc6QTNizszN NUH4bmtsW0GQR1XS
MOLT-16 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFzLkm2PVIh|ryP NGnJSIRUSU6JRWK=
YH-13 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvyTnZ1UUN3ME2xNk4xOzR4IN88US=> M1\PZnNCVkeHUh?=
P12-ICHIKAWA NUHPbZBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTF{LkO4OFUh|ryP NYXDWVE5W0GQR1XS
GR-ST NE\zTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DLXWlEPTB;MUKuOVI6PSEQvF2= MYfTRW5ITVJ?
CAKI-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T6NmlEPTB;MUKuO|kyKM7:TR?= NF7oUJBUSU6JRWK=
LXF-289 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\6T2NSUUN3ME2xN{4xQDN3IN88US=> NHu5UGdUSU6JRWK=
MHH-PREB-1 Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn72TWM2OD1zMz6yO|A1KM7:TR?= MWXTRW5ITVJ?
EW-16 MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInp[oFKSzVyPUGzMlMyQDdizszN NV;VN3UzW0GQR1XS
NCI-H82 NWHvd5d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF62d2NKSzVyPUGzMlQyQTVizszN NX3ofHVGW0GQR1XS
MMAC-SF NHPXZ|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vUXmlEPTB;MUOuOFU1PyEQvF2= MXLTRW5ITVJ?
COLO-684 Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ruU2lEPTB;MUOuOVMyQCEQvF2= MX\TRW5ITVJ?
QIMR-WIL NITNW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTQbYJKSzVyPUGzMlgyODlizszN NXzROoFyW0GQR1XS
NB69 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor4TWM2OD1zMz65PFY5KM7:TR?= NVXoXpRXW0GQR1XS
NCI-H2291 NFXJVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;2TWM2OD1zND60OFU{KM7:TR?= NV;4e25mW0GQR1XS
MKN7 NHXEV2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XMS2lEPTB;MUSuOlY4PiEQvF2= MXvTRW5ITVJ?
HDLM-2 MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTF3LkGyPFYh|ryP NFLKVHNUSU6JRWK=
A253 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon4TWM2OD1zNT6zPFY6KM7:TR?= NFro[XpUSU6JRWK=
SK-LU-1 NYjWOHU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33QPGlEPTB;MUWuPVA6PCEQvF2= Ml7qV2FPT0WU
MEG-01 M3;Idmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnudWVPUUN3ME2xOU46OTB5IN88US=> M{DhW3NCVkeHUh?=
SK-N-DZ M4LlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OxfGlEPTB;MUWuPVM4PiEQvF2= MUDTRW5ITVJ?
H4 NX3zOGtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF4LkC4PEDPxE1? MVrTRW5ITVJ?
LU-65 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF4LkOzPFQh|ryP Mo\zV2FPT0WU
NCI-H1048 NHHmUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojmTWM2OD1zNj61NVY2KM7:TR?= MVnTRW5ITVJ?
LCLC-97TM1 NFrxZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz2NXBKSzVyPUG2MlU5QDlizszN NH24VVRUSU6JRWK=
CAL-120 NEfLRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF4Lkm4O|kh|ryP MVHTRW5ITVJ?
LU-134-A MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXoTWM2OD1zNz6zN|kyKM7:TR?= NVvIb3JwW0GQR1XS
SK-MEL-1 NVzzW2Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LPNWlEPTB;MUeuO|EzPyEQvF2= MYLTRW5ITVJ?
NCI-H69 NF;kRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTF5LkmzNFch|ryP M4TrOXNCVkeHUh?=
MC116 NXXj[ZQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF5Lkm3OUDPxE1? NE\XWJdUSU6JRWK=
UMC-11 Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fsTmlEPTB;MUiuNVc5QCEQvF2= Ml3SV2FPT0WU
HCC1395 MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT3N2hKSzVyPUG4MlQ{ODFizszN MXjTRW5ITVJ?
no-10 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK4dYFwUUN3ME2xPE43Ozh6IN88US=> NInYXYxUSU6JRWK=
NY NHjReolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHmzZWVKSzVyPUG5MlA5ODlizszN M4LrcHNCVkeHUh?=
OS-RC-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjVZZJKSzVyPUG5MlEzPTJizszN MmfIV2FPT0WU
D-423MG M4\FNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFr0eIdKSzVyPUG5MlM6PTJizszN NH3YTG9USU6JRWK=
LC-2-ad MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvHWIZKSzVyPUG5Mlc3OTJizszN MWrTRW5ITVJ?
DU-4475 NIfm[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUi3OVR7UUN3ME2xPU45QDV{IN88US=> NVq5WlNOW0GQR1XS
YKG-1 NWDKXJJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fscWlEPTB;MUmuPVYzKM7:TR?= M3LOW3NCVkeHUh?=
HCC1569 M4r2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJyLkK2NlQh|ryP MkHaV2FPT0WU
TYK-nu NE[4TWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3qTWM2OD1{MD6yPFQ4KM7:TR?= MV\TRW5ITVJ?
DEL MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXxTWM2OD1{MD65PFA5KM7:TR?= MnzvV2FPT0WU
MHH-ES-1 NWfteHlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LWUGlEPTB;MkGuN|U6PyEQvF2= MlfTV2FPT0WU
KARPAS-299 NFvMdmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnreG5PUUN3ME2yNU42OjlizszN MnPoV2FPT0WU
CTV-1 NV3hZ|lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XW[WlEPTB;MkGuOlE4OiEQvF2= NVv4clFlW0GQR1XS
NCI-H2452 MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7zZnpKSzVyPUKyMlY3PzdizszN MWHTRW5ITVJ?
D-566MG NIHabnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJ{Lke2NFEh|ryP NELVSG5USU6JRWK=
EFO-27 NVHqTHE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELDRoFKSzVyPUKzMlA3PTFizszN NUPJTnRVW0GQR1XS
NCI-H596 NIPlZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLvN3lKSzVyPUKzMlg2OjdizszN NUHlSnNNW0GQR1XS
KS-1 M2HqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vGVWlEPTB;MkSuNlc2QSEQvF2= MWTTRW5ITVJ?
8305C M{XDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjuSmRKSzVyPUK0MlQxPDVizszN MYLTRW5ITVJ?
A427 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvsdIpKSzVyPUK1MlA{OjNizszN NYLhcIZMW0GQR1XS
COLO-800 M3XVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJ3LkGwOlEh|ryP M3ezZnNCVkeHUh?=
SJRH30 NWj4PGVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDESHZzUUN3ME2yOU4{QTB6IN88US=> NFzX[WhUSU6JRWK=
MEL-HO Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mom5TWM2OD1{NT60N|E6KM7:TR?= NIDYboZUSU6JRWK=
FTC-133 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrGTpR{UUN3ME2yOU45OTh4IN88US=> MonMV2FPT0WU
SF295 NVTR[5ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmruTWM2OD1{Nj6yPVYh|ryP MX\TRW5ITVJ?
SW1710 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW2TWM2OD1{Nj60NVI{KM7:TR?= M3LrenNCVkeHUh?=
EFM-19 NGLhcnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ4LkixOFUh|ryP M1TDOXNCVkeHUh?=
NB10 M375dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfLc5RyUUN3ME2yPE4zOjl5IN88US=> Mn3ZV2FPT0WU
TK10 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfwdpNIUUN3ME2yPE4zOzl7IN88US=> Mn3OV2FPT0WU
D-502MG NFfV[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFO2SW5KSzVyPUK4MlQh|ryP MXjTRW5ITVJ?
EW-18 NYPjdW9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHLc4ZKSzVyPUK4MlQ{QDZizszN NEXweHlUSU6JRWK=
VMRC-RCZ MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXvTWM2OD1{OD65OFEh|ryP MX\TRW5ITVJ?
Ca9-22 M2nmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjMWGx6UUN3ME2yPU41PTV5IN88US=> M4f6eHNCVkeHUh?=
KYSE-70 NUDYfnpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDjTWM2OD1{OT61O|g3KM7:TR?= NFm0TmVUSU6JRWK=
A101D MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m5W2lEPTB;MkmuOlQ4OiEQvF2= NFviclRUSU6JRWK=
WM-115 M3j2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzZXVFQUUN3ME2yPU44PjB5IN88US=> NHfoWolUSU6JRWK=
HCC2157 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLuTWM2OD1{OT64PFA4KM7:TR?= M4C4SHNCVkeHUh?=
TE-9 M1nO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDWZ3pKSzVyPUK5Mlg5PjVizszN M{e0V3NCVkeHUh?=
K-562 Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;mR2lEPTB;M{CuNFk{OyEQvF2= MnjHV2FPT0WU
SN12C MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq4R2tKUUN3ME2zNE4yPDJ4IN88US=> MY\TRW5ITVJ?
ESS-1 NV3xXmxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDkTWM2OD1|MD60O|U6KM7:TR?= M3ziTHNCVkeHUh?=
K5 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmruTWM2OD1|MD63OlQh|ryP NVrYWo5nW0GQR1XS
J82 M{\pTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTENnVoUUN3ME2zNU4xQDl5IN88US=> NF[1fVJUSU6JRWK=
HOP-92 NH36SplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTNzLkGxNVEh|ryP MX;TRW5ITVJ?
NCI-H2228 MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jD[GlEPTB;M{GuN|I6PiEQvF2= MVHTRW5ITVJ?
OCI-AML2 MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFezSIhKSzVyPUOxMlM3OSEQvF2= NFXod41USU6JRWK=
NCI-SNU-5 NH2zeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEOzdXFKSzVyPUOxMlgyOzdizszN M{TSPXNCVkeHUh?=
A3-KAW MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXITWM2OD1|MT65NlQ{KM7:TR?= MYrTRW5ITVJ?
LCLC-103H NYHzW4JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHxTWM2OD1|Mj6wNVcyKM7:TR?= MkCxV2FPT0WU
KY821 NWjme2d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO2TWM2OD1|Mj62PFg1KM7:TR?= MlXTV2FPT0WU
JVM-2 NIXaU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfCR3lnUUN3ME2zNk46ODd7IN88US=> NYPQNWlHW0GQR1XS
Mo-T M2jXR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXwXmRWUUN3ME2zN{4yODB3IN88US=> NFnOZlZUSU6JRWK=
IA-LM NH21TIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rtd2lEPTB;M{OuNlc2KM7:TR?= NUPSe|ZPW0GQR1XS
C8166 NHrUSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzkRW5oUUN3ME2zN{4{OTl{IN88US=> NH;jOYlUSU6JRWK=
TCCSUP M{SxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT3Wpo6UUN3ME2zN{41OzB5IN88US=> MWDTRW5ITVJ?
JEG-3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrhUYdKSzVyPUOzMlQ4PjhizszN M3fJSHNCVkeHUh?=
MS-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ezb2lEPTB;M{OuOVU2OSEQvF2= NEfXT|dUSU6JRWK=
NCI-H1304 NEfwcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXNVVNsUUN3ME2zN{42PzJ3IN88US=> MY\TRW5ITVJ?
Ramos-2G6-4C10 MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTN2LkCzN|Uh|ryP M4juSXNCVkeHUh?=
MDA-MB-453 M{LqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr2UmhRUUN3ME2zOE43Ozl3IN88US=> M4fNVHNCVkeHUh?=
KYSE-520 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\3TWM2OD1|ND63NVgyKM7:TR?= NUn4bJdMW0GQR1XS
SW900 NXzn[HRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXThXm9OUUN3ME2zOE45OTF3IN88US=> M1;RXHNCVkeHUh?=
HCC2998 NFzxSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7OTWM2OD1|NT6xOVI6KM7:TR?= MXjTRW5ITVJ?
A2058 NXHOcpBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fZSGlEPTB;M{WuOlA3OSEQvF2= MYrTRW5ITVJ?
OVCAR-3 NH7YPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTN4LkKwOFUh|ryP M3e5c3NCVkeHUh?=
MOLT-4 NWrh[HFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrBXnFKSzVyPUO2MlIzQTRizszN NVLVO|AxW0GQR1XS
CAPAN-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLuTWM2OD1|Nj60Olk6KM7:TR?= NXrMepJPW0GQR1XS
SCC-9 NH:4WolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TGUWlEPTB;M{euOFAzPyEQvF2= MkDCV2FPT0WU
SF268 MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm1Nm5KSzVyPUO4MlM1OzNizszN NU\IbnRPW0GQR1XS
HGC-27 NV\R[XE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXkboI6UUN3ME2zPE4{PzFzIN88US=> MmnkV2FPT0WU
DOHH-2 M3XtR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1THN2lEPTB;M{iuO|E2QCEQvF2= M1PlSnNCVkeHUh?=
KE-37 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPJW4FHUUN3ME2zPE46QDJ6IN88US=> NVTKfJlmW0GQR1XS
MOLT-13 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Xa[WlEPTB;M{muNlUxOiEQvF2= NH[4OZZUSU6JRWK=
ES1 NV7BfGY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTN7LkO4OUDPxE1? M3;tN3NCVkeHUh?=
SK-OV-3 NE\4N2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTN7Lkm2OFMh|ryP NFq2dXJUSU6JRWK=
SNU-449 NVTMcYhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTRyLkC3OlQh|ryP NVLMPHQ4W0GQR1XS
KYSE-510 NXW3O2E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPsTWM2OD12MD6xNlk2KM7:TR?= M{\4ZXNCVkeHUh?=
HL-60 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf3eWRKSzVyPUSwMlk4QDNizszN NV7NT3c{W0GQR1XS
DJM-1 NXG2OlRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoK0TWM2OD12MD65O|k6KM7:TR?= NUX4RpE6W0GQR1XS
TGBC11TKB NWP0c3lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTRzLkC5NlYh|ryP MV3TRW5ITVJ?
U-2-OS MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn0SGF4UUN3ME20Nk4zPjRzIN88US=> NXi2Rmg{W0GQR1XS
NCI-H2030 NH;4SIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT3UHNKSzVyPUSyMlQ{PjhizszN NV\NeWJrW0GQR1XS
LU-135 NUPYSmNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XvZmlEPTB;NEKuOVQ1PyEQvF2= MWXTRW5ITVJ?
ZR-75-30 NHnCNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[wTWM2OD12Mz6wOFk{KM7:TR?= M4PRfHNCVkeHUh?=
GT3TKB NXHTWZJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTR|LkK2O|kh|ryP NGfiSY5USU6JRWK=
RPMI-2650 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLCTWM2OD12Mz63PFE3KM7:TR?= MXnTRW5ITVJ?
SAS MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTR|Lkm1N|Qh|ryP MVHTRW5ITVJ?
MDA-MB-231 NHeyVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;qT3NKSzVyPUSzMlk3ODlizszN MmHtV2FPT0WU
JVM-3 NF63bmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTR2LkC1N|Mh|ryP NXTDPZhuW0GQR1XS
COLO-320-HSR NHjDWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDrc5F2UUN3ME20OE42PjN|IN88US=> MnfGV2FPT0WU
SNB75 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTR2Lk[xNFUh|ryP MnfsV2FPT0WU
NCI-H441 MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rEVWlEPTB;NESuPVMzQCEQvF2= MkjrV2FPT0WU
HCT-116 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDjTWM2OD12ND65PFY5KM7:TR?= MofvV2FPT0WU
NCI-H226 MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[0bGdKSzVyPUS1MlY{PjhizszN MXvTRW5ITVJ?
CAL-33 NILafmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknrTWM2OD12NT65NlE4KM7:TR?= NITC[mdUSU6JRWK=
NCI-H1437 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoflTWM2OD12Nj6zNlEh|ryP M4TqXnNCVkeHUh?=
HCC1187 MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXJbVZ2UUN3ME20Ok41OjV3IN88US=> MYHTRW5ITVJ?
NUGC-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37s[GlEPTB;NE[uOVcxQSEQvF2= NYDUXZNyW0GQR1XS
T98G M1jx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\DU4dKSzVyPUS3MlU1PyEQvF2= NX;XZYtJW0GQR1XS
OVCAR-8 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLzTWM2OD12Nz62PFMh|ryP Mlr3V2FPT0WU
LB2241-RCC M1TPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jrN2lEPTB;NEeuO|I4KM7:TR?= NEixdYFUSU6JRWK=
NCI-H358 NFXxfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLRRVdQUUN3ME20PE4yOTV{IN88US=> NF\XU2tUSU6JRWK=
PANC-08-13 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rLNmlEPTB;NEiuNVg2OyEQvF2= MY\TRW5ITVJ?
KP-N-YN NGLlWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHGTWM2OD12OD6yNVAzKM7:TR?= MV3TRW5ITVJ?
NCI-H1755 MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XtS2lEPTB;NEiuNlczPiEQvF2= NELFS3dUSU6JRWK=
NCI-N87 M2HPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf2cG9KSzVyPUS4MlI6QTFizszN NF:zRm9USU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pFGFR2 / FGFR2 ; 

PubMed: 24968263     


PD173074 and MK2461 inhibit FGFR2 phosphorylation. Cells were treated for 1 hour with a titration of PD173074 as described in Materials and methods. Lysates were prepared and 50 ug protein was subjected to SDS-PAGE and western blotting with phospho Y653/654 FGFR and MAB6841 total FGFR2 antibody.

p-S6RP / p-PRAS40 / p-p105 NFKB / P105 NFKB / P50 NFKB / p-AMPK / p-CRK II / p-PDK1; 

PubMed: 24968263     


Time course of inhibition for multiple signaling proteins. NCI-H716 cells were treated with 100 nM PD173074 for the indicated times and signaling pathways were analyzed by SDS PAGE and western blotting. 100 nM PD173074 was selected because this amount caused full inhibition of pERK at the 2 hour time point. “p” indicates phosphoprotein, and the phosphorylation sites are listed in Methods. Terminology on the right side of figure groups proteins according to the time at which inhibition or protein loss occurs.

24968263
Growth inhibition assay
Cell viability; 

PubMed: 24968263     


B. PD173074 and MK2461 inhibit NCI-H716 cell growth. Cell lines were plated at 4000 cells/well and incubated overnight. NCI-H716 cells were treated with a titration of PD173074 as described in Materials and Methods. Cell growth was measured with Vialight reagent, and growth was presented relative to untreated cells. C. PD173074 and MK2461 selectively inhibit growth of NCI-H716 cells. Colon cancer cell lines listed were plated at 4000 cells/well and 24 hours later were treated with a titration of compounds. 4 days later cell growth was measured with vialight and IC50s were calculated from graph pad prism. 

24968263
In vivo Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. [1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. [4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. [5]

Protocol

Kinase Assay:[1]
- Collapse

In vitro kinase inhibition assays:

Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl2, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-32P]ATP (5 μM ATP containing 0.4 μCi of [γ-32P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [32P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.
Cell Research:[4]
- Collapse
  • Cell lines: KMS11 and KMS18
  • Concentrations: Dissolved in DMSO, final concentrations ~100 nM
  • Incubation Time: 48 hours
  • Method: Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Swiss Webster mice with induced corneal angiogenesis
  • Dosages: ~2 mg/kg/day
  • Administration: Administered intraperitoneally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (190.95 mM)
Ethanol 100 mg/mL (190.95 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 523.67
Formula

C28H41N7O3

CAS No. 219580-11-7
Storage powder
in solvent
Synonyms N/A
Smiles CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the half-life of PD173074(S1264) in vivo?

  • Answer:

    According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Related FGFR Products

Tags: buy PD173074 | PD173074 supplier | purchase PD173074 | PD173074 cost | PD173074 manufacturer | order PD173074 | PD173074 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID